PDF
XLS
DOC
DOC
Johnson & Johnson Pricing Transparency Report
View report
Transparency report
Prescription drug net pricing
As net prices decline
Our R&D investments
What we believe
Citations
Fast facts
2022 Executive summary
2022 at a glance
$39 Billion: breaking it down
Rebates, discounts and fees provided to intermediaries
PDABs and UPLs
The 340B program
Archive
Menu
Archive
View report
Transparency report
Prescription drug net pricing
As net prices decline
Our R&D investments
What we believe
Citations
Fast facts
2022 Executive summary
2022 at a glance
$39 Billion: breaking it down
Rebates, discounts and fees provided to intermediaries
PDABs and UPLs
The 340B program
Archive Page
Summbit
Influence of PDABs and UPLs on the State Drug Pricing Ecosystem
2022 Janssen Transparency Report
May 25, 2023
How Insurers Divert Co-Pay Support Meant for Patients
May 25, 2023
The 340B Program
2021 Janssen U.S. Transparency Report
2020 Janssen US Transparency Report Executive Summary
2020 Janssen US Transparency Report
2016 Janssen US Transparency Report Executive Summary
2016 Janssen US Transparency Report
2017 Janssen US Transparency Report Executive Summary
2017 Janssen US Transparency Report
2018 Janssen US Report Executive Summary
2018 Janssen US Transparency Report
April 1, 2019
2019 Janssen US Transparency Report Executive Summary
April 1, 2019
Janssen 2019 Transparency Report
